Literature DB >> 26996557

Lymphangiogenesis in Breast Cancer Correlates with Matrix Stiffness on Shear-Wave Elastography.

Yoon Jin Cha1, Ji Hyun Youk2, Baek Gil Kim1, Woo Hee Jung3, Nam Hoon Cho4.   

Abstract

PURPOSE: To correlate tumor stiffness and lymphangiogenesis in breast cancer and to find its clinical implications.
MATERIALS AND METHODS: A total of 140 breast cancer patients were evaluated. Tumor stiffness was quantitatively measured by shear-wave elastography in preoperative ultrasound examination, calculated as mean elasticity value (kPa). Slides of resected breast cancer specimens were reviewed for most fibrotic area associated with tumor. D2-40 immunohistochemical staining was applied for fibrotic areas to detect the lymphatic spaces. Microlymphatic density, tumor stiffness, and clinicopathologic data were analyzed.
RESULTS: Higher elasticity value was associated with invasive size of tumor, microlymphatic density, histologic grade 3, absence of extensive intraductal component, presence of axillary lymph node metastasis, and Ki-67 labeling index (LI) in univariate regression analysis, and associated with Ki-67 LI and axillary lymph node metastasis in multivariate regression analysis. Microlymphatic density was associated histologic grade 3, mean elasticity value, and Ki-67 LI in univariate regression analysis. In multivariate regression analysis, microlymphatic density was correlated with mean elasticity value.
CONCLUSION: In breast cancer, tumor stiffness correlates with lymphangiogenesis and poor prognostic factors.

Entities:  

Keywords:  Breast neoplasms; elasticity imaging techniques; fibrosis; lymphangiogenesis

Mesh:

Year:  2016        PMID: 26996557      PMCID: PMC4800347          DOI: 10.3349/ymj.2016.57.3.599

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


INTRODUCTION

Fibrosis of tumors contributes to invasion and progression thereof.1 As a tumor grows, intratumoral hypoxia is induced, and the hypoxia-inducible factor (HIF)-1α pathway is activated. Concomitantly, abnormally activated tumor fibroblasts activate vascular endothelial growth factor (VEGF), which induces (lymph)angiogenesis.2 Hypoxia also induces Wnt/beta-catenin signaling. Studies have demonstrated that activated beta-catenin is associated with metastatic potential and poor prognosis in several cancers.34 In breast cancer, tumor fibrosis has been shown as a surrogate marker for hypoxia and (lymph)angiogenesis.56 Fibrotic tumor stroma induces angiogenesis by promoting the expression of hypoxia-related genes, resulting in tumor progression and metastasis via lymphovascular invasion.78 Screening breast ultrasound (US) plays an important role in detection of early breast cancer.9 Recently, shear-wave elastography (SWE) has been used to evaluate breast mass stiffness during routine US examination since the method helps to differentiate benign from malignant masses.1011 As the elasticity value reflects the hardness of an object and has been found to correlate with fibrosis, SWE is also used to screen for prostate cancer1213 and evaluate for liver fibrosis in patients with hepatitis and primary biliary cirrhosis.14 Moreover, as SWE takes great advantage of quantitative estimation, statistical analyses of the correlation between various histologic parameters and tumor stiffness are possible. Studies investigating the association between a higher elasticity value and higher rate of prediction of cancer diagnosis have been reported.151617 In this study, we aimed to correlate lymphangiogenesis with the stiffness of breast cancers and to analyze the value of predicting lymph node metastasis and other clinicopathologic parameters.

MATERIALS AND METHODS

Patients and clinicopathologic data

This study has been approved by the Institutional Review Board of Severance Hospital (IRB No. 4-2015-0113). Between July 2012 and March 2013, 639 breast masses were imaged by gray-scale US and SWE. Core needle biopsy demonstrated breast cancer in 150 patients, who subsequently underwent mastectomy with axillary lymph node dissection. After excluding 10 patients who had received neoadjuvant chemotherapy, data from 140 patients were analyzed in this study. Pathology reports of the preoperative biopsy and mastectomy specimens were reviewed and hematoxylin and eosin slides of resected specimen were reviewed to determine the histologic type, invasive size, extensive intraductal component (EIC, defined as occupying 25% or more of the tumor area), histologic grade, lymphovascular invasion, and axillary lymph node metastasis.

SWE examinations

Breast US examinations were performed using the Aixplorer US system (SuperSonic Imagine, Aix-en-Provence, France), which was equipped with a 4–15-MHz linear-array transducer, by one of four radiologists with 5–10 years of experience in breast US exams. The investigators were aware of the clinical examination and mammography results at the time of examination. After obtaining gray-scale US, SWE images were obtained for breast masses that were scheduled for biopsy or surgical excision. The built-in region-of-interest (ROI) (Q-box; SuperSonic Imagine) of the system was set to include the lesion and surrounding normal tissue, which was displayed as a gray-scale image overlaid with a semitransparent color map of tissue stiffness, ranging from dark blue, which indicated the lowest stiffness, to red, which indicated the highest stiffness (0–180 kPa). Areas of black on the SWE images represented tissue in which no shear wave was detected. Fixed 2×2-mm ROIs were placed by an investigator over the stiffest part of the lesion, including immediate adjacent stiff tissue or halo. The system calculated the mean elasticity values in kPa for the mass.

Interpretation of immunohistochemistry and HER2 fluorescence in situ hybridization evaluation

For the immunohistochemical evaluation of ER, PR, HER2, and Ki-67 labeling index (LI) status, formalin-fixed, paraffin-embedded (FFPE) tissue sections obtained from the surgical specimens were stained with appropriate antibodies for ER (clone 6F11; 1:200; Novocastra, Newcastle upon Tyne, UK), PR (clone 16; 1:200; Novocastra), Ki-67 (clone MIB-1; 1:1000; Dako, Glostrup, Denmark), HER2 (clone 4B5; prediluted; Roche diagnostics). A cut-off value of ≥1% positively stained nuclei was used to define ER and PR positivity.9 HER2 staining was analyzed according to the American Society of Clinical Oncology/College of American Pathologists guidelines, using the following categories: 0=no immunostaining; 1+=weak incomplete membranous staining in <10% of the tumor cells; 2+=complete membranous staining, either uniform or weak, in ≥10% of the tumor cells; and 3+=uniform intense membranous staining in ≥30% of the tumor cells.18 HER2 immunostaining was considered positive when strong (3+) membranous staining was observed, whereas 0 or 1+ cases were considered negative. Tumors with a score of 2+ were sent for fluorescence in situ hybridization (FISH) testing performed using the PathVysion HER2 DNA Probe Kit (Abbott-Vysis, Des Plaines, IL, USA). This test determines the HER2 amplification in the event the ratio of the HER2 gene signal to chromosome 17 signal is more than 2, which is classified as positive. Based on immunohistochemistry or FISH results of ER, PR, HER2, and Ki-67 LI status, the tumors were divided into four subtypes: luminal A (ER-positive and/or PR-positive, HER2-negative, and Ki-67 LI<14%); luminal B (ER-positive and/or PR-positive, HER2-negative, and Ki-67 LI ≥14% or ER-positive and/or PR-positive and HER2-positive, irrespective of Ki-67 LI); HER2-enriched (ER-negative, PR-negative, and HER2-positive); and triple-negative breast cancer (TNBC) (ER-negative, PR-negative, and HER2-negative).

Microlymphatic density

To evaluate lymphangiogenesis, available 134 FFPE tissue sections obtained from the surgical specimens were stained with antibodies against D2-40 (1:100; Dako). Immunohistochemical staining for D2-40 was performed on the most fibrotic area aro-und the tumor (Fig. 1). Each stained slide was examined at 100× magnification and counted for lymphatic spaces. Completely D2-40 surrounded spaces without containing red blood cells were counted.
Fig. 1

Lymphangiogenesis in fibrous stroma in tumor with high elasticity value and low elasticity value. In tumor with high elasticity value (case 19, mean elasticity value: 230.0 kPa) shows lymphatic spaces (maximal microlymphatic density: 23.0) embedded in fibrotic tumor stroma (A), which are highlighted by D2-40 immunohistochemical staining (B). In tumor with low elasticity value (case 116, mean elasticity value: 56.5 kPa), lymphatic space is rarely found in fibrotic area (C) by D2-40 staining (D) (arrowheads).

Statistical analysis

The mean elasticity value (calculated using SWE) and microlymphatic density were correlated with clinicopathologic parameters using univariate and multivariate regression models. Data were analyzed using the statistical software SPSS (version 20, SPSS Inc., Chicago, IL, USA). Differences with p<0.05 were considered statistically significant.

RESULTS

The mean age of the 140 patients included in this study was 52.7 years (range 28–81 years). The mean elasticity value was 141.90 kPa (range 16.10–294.30 kPa). The mean of maximal number of lymphatic spaces was 13.48 (range 1–53). The histological cancer types were as follows: invasive ductal carcinoma (n=111, 79.3%), invasive lobular carcinoma (n=7, 5.0%), and others (n=22, 15.7%; four medullary, four tubular, three mucinous, two micropapillary, two papillary, two pleomorphic, two cribriform, one apocrine, one metaplastic, and one solid papillary). Based on immunohistochemistry or FISH results of ER, PR, HER2, and Ki-67 LI status, the molecular cancer types were as follows: luminal A (n=64, 45.7%), luminal B (n=18, 12.9%), HER2 (n=32, 22.9%), and TNBC (n=26, 18.6%). By univariate regression analysis, mean elasticity value was positively correlated with the invasive tumor size, histologic grade 3, Ki-67 LI, axillary lymph node metastasis, and microlymphatic density, and negatively correlated with EIC (Table 1). No significant differences were found among histologic or molecular types of tumor. Lymphovascular invasion showed tendency of correlation with the mean elasticity value. Microlymphatic density was associated significantly with mean elasticity value, histologic grade 3, and Ki-67 LI (Table 2). By multivariate regression analysis, axillary lymph node metastasis (p=0.03) and Ki-67 LI (p=0.045) were significantly correlated with mean elasticity value (Table 3). In terms of lymphangiogenesis, significant correlation was observed between mean elasticity value and maximal microlymphatic density (p=0.044) (Table 4). However, histologic grade, axillary lymph node metastasis, EIC, and Ki-67 LI did not correlate with maximal microlymphatic density.
Table 1

Results from Univariate Regression Analysis of Clinicopathological Variables and the Mean Elasticity Value

VariableNumber (total=140)Mean elasticity value (kPa)β coefficientp value
Age-0.122±0.3760.745
Size of invasive tumor12.49±3.840.001
Maximal microlymphatic density1.106±0.4960.027
Histologic type
 Ductal111142.52±52.266.84±11.980.569
 Lobular7151.74±39.1716.07±22.280.472
 Specified22135.68±49.470
Molecular type
 Luminal A64135.89±40.120
 Luminal B18151.57±70.6015.67±13.680.254
 HER232143.56±56.027.66±11.100.491
 TNBC26147.97±54.4812.07±11.930.313
Histologic grade
 129122.25±48.800
 278140.56±51.9518.31±10.800.092
 333162.35±44.3840.10±12.630.002
Extensive intraductal component38126.14±47.70-21.45±9.570.027
Axillary lymph node metastasis40165.23±57.4732.65±9.180.001
Lymphovascular invasion18161.94±62.2322.99±12.790.075
ER
 Negative42147.82±55.520
 Positive98139.37±49.13-8.45±9.430.371
PR
 Negative60146.53±54.760
 Positive80138.43±48.19-8.10±8.730.355
HER2
 Negative108141.41±49.790
 Positive32143.56±56.022.14±10.620.836
p53
 Negative72139.50±49.720
 Positive68144.44±52.734.94±8.660.569
Ki-67 labeling index0.857±0.280.003

TNBC, triple-negative breast cancer.

Table 2

Results from Univariate Regression Analysis of Clinicopathological Variables for Lymphangiogenesis in Breast Cancer

VariableNumber (total=134)Maximal microlymphatic densityβ coefficientp value
Age-0.09±0.070.154
Size of invasive area0.78±0.690.258
Mean elasticity value0.033±0.0150.027
Histologic type
 Ductal10713.93±9.051.49±2.140.490
 Lobular79.43±6.24-3.02±3.860.435
 Specified2012.45±7.980
Molecular type
 Luminal A6112.21±6.490
 Luminal B1813.94±12.301.73±2.360.465
 HER23014.67±9.092.45±1.970.214
 TNBC2514.80±10.412.59±2.090.219
Histologic grade
 12611.62±6.550
 27612.95±9.351.33±1.980.502
 33216.25±8.614.64±2.300.046
Extensive intraductal component3814.74±9.741.76±1.690.299
Axillary lymph node metastasis3915.03±10.182.18±1.670.193
Lymphovascular invasion1816.78±12.933.81±2.210.087
ER
 Negative4115.22±10.140
 Positive9312.71±8.07-2.51±1.640.128
PR
 Negative5914.10±9.150
 Positive7512.99±8.54-1.12±1.530.468
HER2
 Negative10413.13±8.720
 Positive3014.67±9.091.53±1.830.403
p53
 Negative6812.15±7.440
 Positive6614.85±9.872.70±1.510.075
Ki-67 labeling index0.11±0.050.030

TNBC, triple-negative breast cancer.

Table 3

Results from Multivariate Regression Analysis of Clinicopathologic Variables and the Mean Elasticity Value

Variableβ coefficientp value
Ki-67 labeling index0.57±0.280.045
Axillary lymph node metastasis28.0±9.160.003
Maximal microlymphatic density0.84±0.480.085
Extensive intraductal component-16.15±9.310.085
Table 4

Results from Multivariate Regression Analysis of Clinicopathologic Variables for Lymphangiogenesis in Breast Cancer

Variableβ coefficientp value
Mean elasticity value0.03±0.020.044
Ki-67 labeling index0.10±0.050.058
Extensive intraductal component2.91±1.680.085

DISCUSSION

In this study, we aimed to correlate tumor stiffness, measured by SWE, with clinicopathologic parameters and lymphangiogenesis of breast cancer. As shown in the previous studies, large invasive size, axillary lymph node involvement, higher histologic grade, increased proliferative index, lymphovascular invasion were significantly correlated with higher elasticity value.10111920 However, the EIC showed a negative correlation with the mean elasticity value in our study. This might be due to the lack of a desmoplastic reaction in intraductal component, in contrast to the invasive tumor which induces desmoplastic fibrosis and higher elasticity value. Also, there was no significant correlation between histologic and molecular subtypes with tumor thickness. According to Chang, et al.,10 tumor elasticity varied significantly based on histologic subtypes. Contrastingly, Youk, et al.19 reported no significant correlation between tumor elasticity and histologic and molecular subtypes. These contradictory results indicate the requirement for further precise investigation into whether histologic and molecular subtypes correlate with tumor stiffness. Multivariate regression analysis demonstrated that axillary lymph node metastasis was independently associated with high elasticity value, which was consistent with an earlier study that reported high elasticity value as an independent predictive factor of axillary lymph node metastasis.21 Also, studies have also shown that a higher histologic grade, large invasive size, and histologic subtypes of TNBC and HER2 types correlate independently with a higher elasticity value.101119 However, in this study, only axillary lymph node metastasis was independently correlated with high elasticity value, which may be attributed to our relatively small sample size. In a prior study, Youk, et al.19 showed that Ki-67 LI in tumor cells correlated with higher elasticity value in univariate regression analysis, while multivariate analysis showed only a tendency towards correlation. However, our data showed a significant association between Ki-67 LI and elasticity value. This discordance might originate from different methods of data analysis used in the two studies: we analyzed Ki-67 LI as a continuous variable, whereas Youk, et al.19 divided patients into two groups according to Ki-67 LI, namely Ki-67>14% and Ki-67≤14%. Lymphangiogenesis was found to be strongly associated with higher elasticity value, histologic grade, and Ki-67 LI in univariate regression analysis. Higher histologic grade and Ki-67 LI are frequently observed in malignant tumors, which are associated with poor prognosis,22 which exhibit rapid progression, frequent metastasis, and (lymph)angiogenesis.2324 However, axillary lymph node metastasis was not found to be correlated with lymphangiogenesis in univariate and multivariate regression analyses in present study. Only the mean elasticity value was independently correlated with lymphangiogenesis. This result suggests that tumor stiffness is important for developing new lymphatic spaces, which is consistent with prior studies in the literature demonstrating an association between tumor fibroblast and hypoxia with (lymph)angiogenesis.525 Apart from metastasis, Lee, et al.18 reported that breast cancer patients having multiple primary cancers show poor prognosis, although the breast cancer was at an early stage. It would be worthy to analyze the elasticity value of patients with multiple primary cancers and correlate the elasticity value and clinicopathologic characteristics of those patients. Fibrosis observed in the center and periphery of tumors correlates well with elasticity value. In malignant tumors, the extracellular matrix (ECM) induces abnormal crosslinking of collagen, which could explain the higher elasticity value observed in malignant tumors. ECM-induced activation of the phosphoinositide 3-kinase pathway is thought to play an important role in tumor cell invasion.24 Fibrotic foci in cancer have also been shown to be associated with poor prognosis, as well as lymphangiogenesis and angiogenesis.1526 Unlike normal fibroblasts in the wound healing process, tumor fibroblasts are continuously activated. VEGF is critical in the development of this reactive stroma in tumors. Additionally, intratumoral hypoxia induces activation of the HIF-1α pathway, and VEGF induces angiogenesis.7 More angiogenesis is induced as the fibrotic area of the tumor expands, which could be the result of interaction between the tumor stroma and intratumoral hypoxia.25 In addition, expression of carbonic anhydrase IX, a hypoxia marker, has been found to be associated with tumor fibrosis.27 In previous studies, HIF-1α and VEGF induce lymphangiogenesis and angiogenesis, that these two hypoxia-related molecules are thought to be linked to tumor aggressiveness and poor prognosis.628 In this study, we confirmed that mean elasticity value correlated significantly with poor prognostic factors. Additionally, we found that tumor stiffness was independently correlated with lymphangiogenesis. Our data also suggest that tumor stiffness measured by SWE may be related to hypoxia-related gene expression and activation of cancer fibroblasts, which could be potential targets by therapeutic strategies for treating cancer. In conclusion, lymphangiogenesis in breast cancer correlated significantly with the mean elasticity value, which reflects tumor stiffness and poor prognosis.
  28 in total

1.  Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study.

Authors:  Ilse Van der Auwera; Gert G Van den Eynden; Cecile G Colpaert; Steven J Van Laere; Peter van Dam; Eric A Van Marck; Luc Y Dirix; Peter B Vermeulen
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

2.  Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis.

Authors:  Liang Liu; Xiao-Dong Zhu; Wen-Quan Wang; Yuan Shen; Yi Qin; Zheng-Gang Ren; Hui-Chuan Sun; Zhao-You Tang
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

3.  Invasive breast cancer: relationship between shear-wave elastographic findings and histologic prognostic factors.

Authors:  Andrew Evans; Patsy Whelehan; Kim Thomson; Denis McLean; Katrin Brauer; Colin Purdie; Lee Baker; Lee Jordan; Petra Rauchhaus; Alastair Thompson
Journal:  Radiology       Date:  2012-04-20       Impact factor: 11.105

4.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 5.  A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation.

Authors:  G G Van den Eynden; C G Colpaert; A Couvelard; F Pezzella; L Y Dirix; P B Vermeulen; E A Van Marck; T Hasebe
Journal:  Histopathology       Date:  2007-06-26       Impact factor: 5.087

6.  Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer.

Authors:  Gert G Van den Eynden; Marcel Smid; Steven J Van Laere; Cecile G Colpaert; Ilse Van der Auwera; Trinh Xuan Bich; Peter van Dam; Michael A den Bakker; Luc Y Dirix; Eric A Van Marck; Peter B Vermeulen; John A Foekens
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

Review 7.  Prostate cancer diagnosis: value of real-time elastography.

Authors:  Leo Pallwein; Fritz Aigner; Ralph Faschingbauer; Eva Pallwein; Germar Pinggera; Georg Bartsch; Georg Schaefer; Peter Struve; Ferdinand Frauscher
Journal:  Abdom Imaging       Date:  2008 Nov-Dec

Review 8.  A tense situation: forcing tumour progression.

Authors:  Darci T Butcher; Tamara Alliston; Valerie M Weaver
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

9.  First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours.

Authors:  I Van der Auwera; Y Cao; J C Tille; M S Pepper; D G Jackson; S B Fox; A L Harris; L Y Dirix; P B Vermeulen
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

10.  Screening Ultrasound in Women with Negative Mammography: Outcome Analysis.

Authors:  Ji-Young Hwang; Boo-Kyung Han; Eun Young Ko; Jung Hee Shin; Soo Yeon Hahn; Mee Young Nam
Journal:  Yonsei Med J       Date:  2015-09       Impact factor: 2.759

View more
  6 in total

1.  Quantitative analysis of shear wave elastic heterogeneity for prediction of lymphovascular invasion in breast cancer.

Authors:  Yini Huang; Yubo Liu; Yun Wang; Xueyi Zheng; Jing Han; Qian Li; Yixin Hu; Rushuang Mao; Jianhua Zhou
Journal:  Br J Radiol       Date:  2021-09-03       Impact factor: 3.039

2.  Added Value of Viscoelasticity for MRI-Based Prediction of Ki-67 Expression of Hepatocellular Carcinoma Using a Deep Learning Combined Radiomics (DLCR) Model.

Authors:  Xumei Hu; Jiahao Zhou; Yan Li; Yikun Wang; Jing Guo; Ingolf Sack; Weibo Chen; Fuhua Yan; Ruokun Li; Chengyan Wang
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

3.  Compression-induced expression of glycolysis genes in CAFs correlates with EMT and angiogenesis gene expression in breast cancer.

Authors:  Baek Gil Kim; Jin Sol Sung; Yeonsue Jang; Yoon Jin Cha; Suki Kang; Hyun Ho Han; Joo Hyun Lee; Nam Hoon Cho
Journal:  Commun Biol       Date:  2019-08-14

4.  Inhibition of matrix stiffness relating integrin β1 signaling pathway inhibits tumor growth in vitro and in hepatocellular cancer xenografts.

Authors:  Changsong Wang; Xiaozhong Jiang; Bin Huang; Wenhao Zhou; Xiao Cui; Chenghong Zheng; Fenghao Liu; Jieling Bi; Yi Zhang; Hong Luo; Lin Yuan; Jianyong Yang; Yu Yu
Journal:  BMC Cancer       Date:  2021-11-25       Impact factor: 4.430

5.  Relationship of shear wave elastography anisotropy with tumor stem cells and epithelial-mesenchymal transition in breast cancer.

Authors:  Xiaoling Leng; Rexida Japaer; Haijian Zhang; Mila Yeerlan; Fucheng Ma; Jianbing Ding
Journal:  BMC Med Imaging       Date:  2021-11-17       Impact factor: 1.930

6.  Fucoxanthin inhibits tumour-related lymphangiogenesis and growth of breast cancer.

Authors:  Jia Wang; Yanhong Ma; Jingshi Yang; Lu Jin; Zixiang Gao; Lingyun Xue; Lin Hou; Linlin Sui; Jing Liu; Xiangyang Zou
Journal:  J Cell Mol Med       Date:  2019-01-16       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.